Co-Authors
This is a "connection" page, showing publications co-authored by Marina Chiara Garassino and Christine Bestvina.
Connection Strength
2.639
-
Management of Autoimmune Conditions Associated With Thymic Epithelial Tumors. J Thorac Oncol. 2026 Jan; 21(1):77-101.
Score: 0.236
-
Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions. Ther Adv Med Oncol. 2025; 17:17588359251323985.
Score: 0.228
-
The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies. Clin Lung Cancer. 2025 Jul; 26(5):429-433.
Score: 0.227
-
Epigenomic exploration of disease status of EGFR-mutated non-small cell lung cancer using plasma cell-free DNA hydroxymethylomes. Cancer Commun (Lond). 2025 Jan; 45(1):51-55.
Score: 0.223
-
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
Score: 0.219
-
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446.
Score: 0.205
-
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. J Clin Oncol. 2023 09 01; 41(25):4093-4096.
Score: 0.202
-
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer. Int J Mol Sci. 2023 May 29; 24(11).
Score: 0.201
-
Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121.
Score: 0.196
-
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis. JTO Clin Res Rep. 2022 Aug; 3(8):100335.
Score: 0.187
-
Quantum machine learning-based electrokinetic mining for the identification of nanoparticles and exosomes with minimal training data. Bioact Mater. 2025 Sep; 51:414-430.
Score: 0.058
-
Delays in phases of care from identification to treatment of suspicious lung nodules. JTCVS Open. 2025 Apr; 24:451-471.
Score: 0.056
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
Score: 0.055
-
The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project. Cancer Med. 2024 May; 13(9):e7159.
Score: 0.054
-
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024 Jul; 19(7):1108-1116.
Score: 0.053
-
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). Lung Cancer. 2023 12; 186:107423.
Score: 0.052
-
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571.
Score: 0.051
-
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126.
Score: 0.046
-
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022 05; 17(5):661-674.
Score: 0.046
-
Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021 03; 9(3).
Score: 0.043